JP2008513436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513436A5 JP2008513436A5 JP2007531869A JP2007531869A JP2008513436A5 JP 2008513436 A5 JP2008513436 A5 JP 2008513436A5 JP 2007531869 A JP2007531869 A JP 2007531869A JP 2007531869 A JP2007531869 A JP 2007531869A JP 2008513436 A5 JP2008513436 A5 JP 2008513436A5
- Authority
- JP
- Japan
- Prior art keywords
- azepino
- indol
- methylamino
- tetrahydro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000010452 phosphate Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- AGPZUEDYVLUKMF-UHFFFAOYSA-N 1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Chemical compound O=C1NCCC2=CNC3=CC=CC1=C23 AGPZUEDYVLUKMF-UHFFFAOYSA-N 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 2
- SRQIXYAZHSQGIT-UHFFFAOYSA-N C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC=C3 Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC=C3 SRQIXYAZHSQGIT-UHFFFAOYSA-N 0.000 claims 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61245904P | 2004-09-22 | 2004-09-22 | |
| US67929605P | 2005-05-09 | 2005-05-09 | |
| PCT/IB2005/002941 WO2006033007A2 (en) | 2004-09-22 | 2005-09-12 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513436A JP2008513436A (ja) | 2008-05-01 |
| JP2008513436A5 true JP2008513436A5 (enExample) | 2008-10-23 |
Family
ID=35526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531869A Pending JP2008513436A (ja) | 2004-09-22 | 2005-09-12 | ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7268126B2 (enExample) |
| EP (1) | EP1799685B1 (enExample) |
| JP (1) | JP2008513436A (enExample) |
| KR (1) | KR100853601B1 (enExample) |
| AR (1) | AR051296A1 (enExample) |
| AT (1) | ATE551345T1 (enExample) |
| AU (1) | AU2005286191B2 (enExample) |
| BR (1) | BRPI0516766A (enExample) |
| CA (1) | CA2581025C (enExample) |
| ES (1) | ES2382950T3 (enExample) |
| IL (1) | IL181463A (enExample) |
| MX (1) | MX2007002461A (enExample) |
| NO (1) | NO337938B1 (enExample) |
| NZ (1) | NZ554659A (enExample) |
| RU (1) | RU2355691C2 (enExample) |
| TW (1) | TWI365188B (enExample) |
| WO (1) | WO2006033007A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| AU2007292387A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| NZ586123A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| KR20100102609A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| KR20100112192A (ko) * | 2008-02-04 | 2010-10-18 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ－매개된 질병을 진단 및 치료하는 방법 |
| KR20170095402A (ko) | 2009-11-09 | 2017-08-22 | 알러간, 인코포레이티드 | 모발 성장을 촉진하기 위한 조성물 및 방법 |
| CA3024216C (en) | 2010-02-12 | 2021-03-30 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| WO2011141909A2 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| AU2014216112B2 (en) | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| RS67356B1 (sr) | 2014-08-22 | 2025-11-28 | Pharma& Schweiz Gmbh | Tablete rukapariba visoke doze |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10875870B2 (en) | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| CN110997068B (zh) | 2017-05-24 | 2022-12-06 | 宾夕法尼亚大学董事会 | 用于成像和放射疗法的经放射标记的荧光parp抑制剂 |
| MX2020004545A (es) * | 2017-11-03 | 2020-08-03 | Sandoz Ag | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. |
| US10933069B2 (en) | 2018-01-05 | 2021-03-02 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| EP3997093A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4100125A1 (en) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph of rucaparib mesylate |
| ES3014370T3 (en) | 2020-04-28 | 2025-04-22 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| EP4182318B1 (en) | 2020-07-14 | 2025-08-27 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib salts |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| AU2022255809A1 (en) | 2021-04-08 | 2023-10-26 | Incozen Therapeutics Pvt. Ltd. | Inhibitors of poly(adp-ribose) polymerase |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US649554A (en) * | 1899-04-08 | 1900-05-15 | Ferdinand Schwedtmann | Electric switch. |
| GB8806449D0 (en) * | 1988-03-18 | 1988-04-20 | Janssen Pharmaceutica Nv | Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones |
| PL210415B1 (pl) * | 1999-01-11 | 2012-01-31 | Agouron Pharma | Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu |
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ATE454893T1 (de) * | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
-
2005
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en not_active Ceased
- 2005-09-12 CA CA2581025A patent/CA2581025C/en not_active Expired - Lifetime
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 EP EP05799991A patent/EP1799685B1/en not_active Expired - Lifetime
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko not_active Expired - Fee Related
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en not_active IP Right Cessation
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en not_active Ceased
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es not_active Expired - Lifetime
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 US US11/233,835 patent/US7268126B2/en not_active Expired - Lifetime
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh not_active IP Right Cessation
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513436A5 (enExample) | ||
| RU2007110026A (ru) | ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА | |
| HRP20151299T1 (hr) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| JP2009502780A5 (enExample) | ||
| WO2009080226A3 (en) | Heterocyclic pyrazole-carboxamides as p2y12 antagonists | |
| HUS1700017I1 (hu) | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok | |
| HRP20170634T4 (hr) | Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida | |
| WO2006062984A3 (en) | Inhibitors of protein kinases | |
| WO2007003521A3 (en) | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| WO2009030467A3 (en) | Saturated and insaturated bi- or tricyclic aryloxyacetamide derivatives and their use as fungicides | |
| JP2005515295A5 (enExample) | ||
| WO2006015860A3 (en) | Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor | |
| JP2008513472A5 (enExample) | ||
| IT1366567B (it) | Granulati espandibili a basemdi polimeri vinilaromatici dotati di migliorata espansibilita'e procedimento per la loro preparazione | |
| WO2007059307A3 (en) | Crystalline and amorphous forms of telithromycin | |
| JP2008515980A5 (enExample) | ||
| WO2007025880A3 (en) | Pyrazolone derivatives as 11-beta hsd1 inhibitors | |
| JP2004315386A5 (enExample) | ||
| JP2008517002A5 (enExample) | ||
| JP2012533539A5 (enExample) | ||
| JP2012511571A5 (enExample) | ||
| JP2006342148A5 (enExample) | ||
| JP2008184368A5 (enExample) | ||
| JP2005281312A5 (enExample) | ||
| WO2006005611A3 (en) | Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents |